Annual report pursuant to Section 13 and 15(d)

Combined and Consolidated Statements of Operations

v3.20.2
Combined and Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development (includes share-based compensation expense) [1] $ 47,927 $ 25,733
General and administrative (includes share-based compensation expense) [2] 18,151 2,692
Total operating expenses 66,078 28,425
Interest expense 625  
Other (income) expense, net (412) 155
Loss before provision for income taxes (66,291) (28,580)
Provision for income taxes 97 19
Net loss $ (66,388) [3] $ (28,599)
Net loss per common share - basic and diluted [4] $ (1.54) $ (1.29)
Weighted-average common shares outstanding – basic and diluted [4] 43,199,191 22,170,862
[1] Includes $159 and $3,582 of costs allocated from Roivant Sciences Ltd. for the years ended March 31, 2020 and 2019, respectively.
[2] Includes $1,381 and $1,180 of costs allocated from Roivant Sciences Ltd. for the years ended March 31, 2020 and 2019, respectively.
[3] Retroactively restated for reverse recapitalization as described in Note 1.
[4] Retroactively restated for the reverse recapitalization as described in Note 1.